We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,492

December 2016 International Trade Compliance
  • Baker McKenzie
  • Global, OECD, United Kingdom, USA, Australia, Canada, European Union
  • December 12 2016

On 29 November 2016, the WTO reported that most WTO members welcomed Ecuador’s efforts to lower its import surcharge rates and reduce the number of


International Trade Compliance Update - September 2016
  • Baker McKenzie
  • Australia, Canada, European Union, United Kingdom, USA
  • September 7 2016

On 19 August 2016, the Russian Federation notified the WTO that it intends to initiate negotiations pursuant to Paragraph 1143 of the Working Party


Cialis Canadian Patent Knocks Out Double Patenting Challenge
  • Bereskin & Parr LLP
  • Canada
  • January 20 2017

Eli Lilly's Canadian patent on treatment of erectile dysfunction with Cialis continues to defy all challengers. A recent appeal case originated from


Litigation - 2016 Year in Review
  • Bereskin & Parr LLP
  • Canada
  • March 8 2017

In 2016, the Federal government proposed changes to the rules that govern litigation, the Federal Courts issued directions for the conduct of


Leave to Appeal to SCC: AstraZeneca Canada Inc et al v Apotex Inc et al (FCCA)
  • Bereskin & Parr LLP
  • Canada
  • March 10 2016

On March 10, 2016, the Supreme Court of Canada granted AstraZeneca Canada Inc.'s ("AstraZeneca") application for leave to appeal from the decision of


Application for Prohibition Granted for Generic Version of Concerta
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

The Court granted Janssen's application prohibiting the Minister of Health from issuing an NOC to Actavis for its generic version of Concerta. The


Biosimilars in Canada: at a tipping point
  • Osler Hoskin & Harcourt LLP
  • Canada
  • May 24 2016

Biosimilars, or highly similar versions of innovative biologic medicines, have now been approved and marketed in developed countries for several


Global Government Solutions 2016: Mid-Year Outlook
  • K&L Gates
  • Australia, Canada, European Union, Germany, Global, United Kingdom, USA
  • July 1 2016

As we issue this 2016 Mid-Year Outlook, the global community has begun to wrestle in earnest with the momentous political, economic, and doing


Prohibition order denied against Apotex for generic tenofovir disoproxilemtricitabine
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • October 31 2016

The Federal Court dismissed Gilead's prohibition application against Apotex for its tenofovir disoproxil fumarate (TDF) and emtricitabine fixed dose


Availability of non-infringing product is relevant in determining profit recovery for infringing activities
  • McCarthy Tétrault LLP
  • Canada
  • February 24 2017

In a recent decision (Apotex Inc. v. ADIR, 2017 FCA 23), the Federal Court of Appeal determined that the Federal Court erred in law by rejecting the